Article · Wikipedia archive · Last revised Jun 28, 2026

CA77.1

CA77.1 (CA) is a synthetic compound that activates chaperone-mediated autophagy (CMA) by increasing the expression of the lysosomal receptor for this pathway, LAMP2A, in lysosomes. CA77.1 is a derivative of earlier compound AR7(HY-101106), which shows potent CMA activation in vitro but is not suitable for in vivo use. CA77.1 is able to activate CMA in vivo, and demonstrates brain penetrance and favorable pharmacokinetics. It has been shown in animal studies that in vivo administration of CA77.1 to enhance chaperone-mediated autophagy, may help to degrade toxic pathogenic protein products such as tau proteins and has potential applications in the treatment of Alzheimer's disease particularly in improving both behavior and neuropathology in PS19 mice models.

Last revised
Jun 28, 2026
Read time
≈ 1 min
Length
276 w
Citations
5
Source
Wikipedia ↗
CA77.1
Solid
Identifiers
  • N-[4-(6-chloroquinoxalin-2-yl)phenyl]acetamide
CAS Number
PubChem CID
ChemSpider
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC16H12ClN3O
Molar mass297.74 g·mol−1
3D model (JSmol)
  • CC(=O)NC1=CC=C(C=C1)C2=CN=C3C=C(C=CC3=N2)Cl
  • InChI=1S/C16H12ClN3O/c1-10(21)19-13-5-2-11(3-6-13)16-9-18-15-8-12(17)4-7-14(15)20-16/h2-9H,1H3,(H,19,21)
  • Key:ZQXMPDVGBWOTBY-UHFFFAOYSA-N

CA77.1 (CA) is a synthetic compound that activates chaperone-mediated autophagy (CMA) by increasing the expression of the lysosomal receptor for this pathway, LAMP2A, in lysosomes. CA77.1 is a derivative of earlier compound AR7(HY-101106), which shows potent CMA activation in vitro but is not suitable for in vivo use.123 CA77.1 is able to activate CMA in vivo, and demonstrates brain penetrance and favorable pharmacokinetics. It has been shown in animal studies that in vivo administration of CA77.1 to enhance chaperone-mediated autophagy, may help to degrade toxic pathogenic protein products such as tau proteins and has potential applications in the treatment of Alzheimer's disease45 particularly in improving both behavior and neuropathology in PS19 mice models.

References

References

  1. Anguiano J, Garner TP, Mahalingam M, Das BC, Gavathiotis E, Cuervo AM (June 2013). "Chemical modulation of chaperone-mediated autophagy by retinoic acid derivatives". Nature Chemical Biology. 9 (6): 374–82. doi:10.1038/nchembio.1230. PMC 3661710. PMID 23584676.
  2. US 9512092, Cuervo AM, Gavathiotis E, Xin Q, Das BC, "Retinoic acid receptor antagonists as chaperone-mediated autophagy modulators and uses thereof", published 18 June 2015, assigned to Albert Einstein College of Medicine of Yeshiva 
  3. WO 2020077024, Cuervo AM, Gavathiotis E, "Benzoxazole and related compounds useful as chaperone-mediated autophagy modulators", published 16 April 2020, assigned to Albert Einstein College of Medicine of Yeshiva 
  4. Bourdenx M, Martín-Segura A, Scrivo A, Rodriguez-Navarro JA, Kaushik S, Tasset I, et al. (April 2021). "Chaperone-mediated autophagy prevents collapse of the neuronal metastable proteome". Cell. 184 (10): 2696–2714.e25. doi:10.1016/j.cell.2021.03.048. PMC 8152331. PMID 33891876.
  5. "WIPO - Search International and National Patent Collections". patentscope.wipo.int.